Company Filing History:
Years Active: 2018-2021
Title: Zhen Ning Wee: Innovator in Cancer Treatment
Introduction
Zhen Ning Wee is a prominent inventor based in Singapore, known for his significant contributions to cancer treatment innovations. He has been awarded 2 patents that focus on novel therapeutic strategies for breast cancer, particularly triple negative breast cancer (TNBC). His work aims to improve patient outcomes through targeted therapies.
Latest Patents
One of Zhen Ning Wee's latest patents is titled "Composition for modulating IRAK1." This invention relates to the treatment of breast cancer, specifically TNBC, using an inhibitor of Interleukin 1 Receptor Associated Kinase 1 (IRAK1), such as ginsenosides. The patent outlines a method for categorizing or determining prognosis in breast cancer patients by assessing the level of IRAK1 nucleic acid, protein, or activity in a sample. It also includes a screening method for identifying compounds that can effectively treat breast cancer by reducing IRAK1 levels.
Another significant patent is "Method of treating cancer," which involves a pharmaceutical composition comprising a histone-lysine N-methyltransferase EZH2 inhibitor and an enhancer of interferon-gamma receptor activity. This invention provides a method for treating patients with cancer through the administration of the described pharmaceutical composition.
Career Highlights
Zhen Ning Wee is affiliated with the Agency for Science, Technology and Research, where he continues to advance his research in cancer therapies. His innovative approaches have the potential to transform treatment protocols and improve the quality of life for cancer patients.
Collaborations
Zhen Ning Wee collaborates with Qiang Yu, contributing to the development of cutting-edge cancer treatment solutions. Their partnership exemplifies the importance of teamwork in scientific research and innovation.
Conclusion
Zhen Ning Wee's work in cancer treatment showcases his dedication to improving patient care through innovative therapies. His patents reflect a commitment to addressing critical challenges in oncology, making him a notable figure in the field of medical research.